Emmessar Biotech & Nutrition
EMMESSARBIOTECHLTD NSE
Emmessar Biotech & Nutrition
ChemicalsNSE: EMMESSARBIOTECHLTD BSE: 524768 Commodity Chemicals
Key Fundamentals
MicrocapCommodity ChemicalsChemicalsMarket Cap
₹12.26 Cr
Volatility
Moderate
P/E Ratio
31
EBITDA
₹-1.35 Cr
Return on Equity
4.1%
Debt to Equity
0
Book Value
₹16.24
EPS
₹1.5
52W High
₹42.75
52W Low
₹18.42
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Strengths
1- Company is almost debt free.
Weaknesses
3- Though the company is reporting repeated profits, it is not paying out dividend
- The company has delivered a poor sales growth of -44.4% over past five years.
- Company has a low return on equity of 6.71% over last 3 years.
Growth Rate
Revenue Growth
-85.77% lower than
3Y
Net Income Growth
33.33% higher than
3Y
Cash Flow Change
-65.63% lower than
3Y
ROE
-59.53% lower than
3Y
ROCE
11.16% higher than
3Y
EBITDA Margin (Avg.)
-239% higher than
3Y
Quarterly Results
| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.07 | 0.08 | 0.33 | 0.08 | 0.08 | 0.34 | 0.1 | 0.1 | 0.09 | 0.09 | 0.09 | 0.09 | 0.06 |
| Expenses | 0.35 | 0.3 | 0.54 | 0.47 | 0.36 | 0.42 | 0.38 | 0.43 | 0.36 | 0.46 | 0.43 | 0.46 | 0.41 |
| Operating Profit | -0.28 | -0.22 | -0.21 | -0.39 | -0.28 | -0.08 | -0.28 | -0.33 | -0.27 | -0.37 | -0.34 | -0.37 | -0.35 |
| OPM % | -400% | -275% | -63.64% | -487.5% | -350% | -23.53% | -280% | -330% | -300% | -411.11% | -377.78% | -411.11% | -583.33% |
| Other Income | 0.46 | 0.53 | 0.53 | 0.48 | 0.46 | 0.51 | 0.43 | 0.61 | 0.53 | 0.54 | 0.49 | 0.47 | 0.54 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.03 | 0.03 | 0.03 | 0.02 |
| PBT | 0.16 | 0.29 | 0.3 | 0.07 | 0.16 | 0.41 | 0.13 | 0.26 | 0.24 | 0.14 | 0.12 | 0.07 | 0.17 |
| Tax % | 68.75% | 31.03% | 56.67% | -285.71% | 43.75% | 31.71% | 84.62% | 126.92% | 25% | 21.43% | 8.33% | 57.14% | 17.65% |
| Net Profit | 0.05 | 0.2 | 0.13 | 0.27 | 0.09 | 0.28 | 0.02 | -0.07 | 0.17 | 0.11 | 0.12 | 0.03 | 0.13 |
| EPS in Rs | 0.1 | 0.4 | 0.26 | 0.54 | 0.18 | 0.56 | 0.04 | -0.14 | 0.34 | 0.22 | 0.24 | 0.06 | 0.26 |
Profit & Loss
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2.19 | 1.98 | 2.61 | 1.27 | 0.63 | 3.4 | 6.99 | 0.36 | 1.02 | 0.56 | 0.61 | 0.37 | 0.33 |
| Expenses | 2.34 | 2.66 | 2.38 | 1.67 | 1.27 | 3.81 | 6.15 | 1.26 | 1.71 | 1.64 | 1.56 | 1.73 | 1.76 |
| Operating Profit | -0.15 | -0.68 | 0.23 | -0.4 | -0.64 | -0.41 | 0.84 | -0.9 | -0.69 | -1.08 | -0.95 | -1.36 | -1.43 |
| OPM % | -6.85% | -34.34% | 8.81% | -31.5% | -101.59% | -12.06% | 12.02% | -250% | -67.65% | -192.86% | -155.74% | -367.57% | -433.33% |
| Other Income | 0.06 | 0.03 | 0.98 | 1.25 | 1.01 | 1.21 | 1.47 | 1.92 | 1.75 | 1.99 | 2.01 | 2.04 | 2.04 |
| Interest | 0 | 0 | 0.01 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0.07 | 0.03 | 0.01 | 0.05 | 0.08 | 0.06 | 0.06 | 0.09 | 0.09 | 0.1 | 0.1 | 0.1 | 0.11 |
| PBT | -0.16 | -0.68 | 1.19 | 0.8 | 0.29 | 0.74 | 2.25 | 0.93 | 0.97 | 0.81 | 0.96 | 0.58 | 0.5 |
| Tax % | -25% | -30.88% | 0% | -15% | -82.76% | -2.7% | 36% | 48.39% | 47.42% | 7.41% | 66.67% | 24.14% | — |
| Net Profit | -0.12 | -0.47 | 1.19 | 0.91 | 0.53 | 0.75 | 1.45 | 0.48 | 0.5 | 0.75 | 0.32 | 0.44 | 0.39 |
| EPS in Rs | -0.24 | -0.94 | 2.38 | 1.82 | 1.06 | 1.5 | 2.9 | 0.96 | 1 | 1.5 | 0.64 | 0.88 | 0.78 |
| Div. Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | — |
Balance Sheet
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Reserves | -3.62 | -4.09 | -2.91 | -2.01 | -1.49 | -0.73 | 0.7 | 1.17 | 1.67 | 2.41 | 2.71 | 3.12 |
| Borrowings | 0 | 0 | 0 | 0 | 0.07 | 0 | 0 | 0 | 0.08 | 0.11 | 0 | 0 |
| Other Liabilities | 1.03 | 1.36 | 1.13 | 0.92 | 1.59 | 1.86 | 2.11 | 1.04 | 1.19 | 1.23 | 1.51 | 1.41 |
| Total Liabilities | 2.41 | 2.27 | 3.22 | 3.91 | 5.17 | 6.13 | 7.81 | 7.21 | 7.94 | 8.75 | 9.22 | 9.53 |
| Fixed Assets | 1.42 | 0.73 | 0.72 | 2.25 | 1.99 | 1.91 | 1.86 | 2.07 | 2 | 1.91 | 1.81 | 1.72 |
| CWIP | 0 | 0 | 0.8 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Other Assets | 0.98 | 1.53 | 1.69 | 1.65 | 3.17 | 4.21 | 5.94 | 5.13 | 5.93 | 6.83 | 7.4 | 7.8 |
| Total Assets | 2.41 | 2.27 | 3.22 | 3.91 | 5.17 | 6.13 | 7.81 | 7.21 | 7.94 | 8.75 | 9.22 | 9.53 |
Cash Flow
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | -0.01 | — | 0.75 | 0.74 | 0.39 | 1.03 | 0.47 | 2.27 | 0.38 | 0.64 | 0.22 | 0.27 |
| Investing | 0 | — | -0.74 | -0.69 | -0.37 | -1.06 | 0.01 | -2.61 | -0.55 | -0.64 | -0.23 | -0.26 |
| Financing | 0 | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0.01 |
| Net Cash Flow | -0.01 | — | 0.01 | 0.05 | 0.01 | -0.03 | 0.48 | -0.34 | -0.17 | 0 | 0 | 0.02 |
| Free Cash Flow | -0.01 | — | -0.06 | -0.04 | 0.39 | 1.03 | 0.47 | 1.96 | 0.35 | 0.64 | 0.22 | 0.26 |
| CFO/OP | 7 | — | 343 | -198 | -61 | -251 | 68 | -284 | -46 | -57 | -25 | -11 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 6.67 | 66.36 | 5.59 | 8.62 | 23.17 | 3.22 | 142 | 10.14 | 3.58 | 13.04 | 11.97 | 19.73 |
| Inventory Days | 336 | 137 | 122 | 52.14 | 2,050 | 273 | 7.24 | 197 | 128 | 164 | 231 | 406 |
| Days Payable | 151 | 76.04 | 76.04 | 5.79 | 1,628 | 190 | 51.7 | 56.15 | 0 | 18.25 | 0 | 40.56 |
| Cash Conversion Cycle | 192 | 127 | 51.22 | 54.97 | 444 | 86.18 | 97.05 | 151 | 131 | 159 | 242 | 385 |
| Working Capital Days | 38.33 | 22.12 | 85.31 | 175 | 458 | 30.06 | 79.37 | -60.83 | 115 | 91.25 | 35.9 | 98.65 |
| ROCE % | -10.81% | -39.3% | 80% | 31.5% | 17.66% | 25.48% | 45.14% | 15.67% | 15.02% | 11.35% | 12.61% | 7.33% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Emmessar Biotech & Nutrition insights
60 extracted metrics + investor summaries across FY09–FY26.
Documents
1
Board Meeting Intimation for Approval Of Audited Results For Quarter And Year Ended March 31, 2026
5 May - Board meeting on May 12, 2026 to approve audited FY2026 financial results; trading window closed till May 14. 5 May - Board meeting on May 12, 2026 to approve audited FY2026 financial results; trading window closed till May 14.
3
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
8 Apr - Company confirms non-applicability of SEBI large corporate framework; outstanding borrowing was NIL as of March 31, 2025. 8 Apr - Company confirms non-applicability of SEBI large corporate framework; outstanding borrowing was NIL as of March 31, 2025.
5
Newspaper Add For Re-Lodgement Of Transfer
Requests Of Physical Shares Under Special Window
10 Mar - Published newspaper notice for SEBI special window to re-lodge physical share transfers; no requests July 2025–Jan 2026. 10 Mar - Published newspaper notice for SEBI special window to re-lodge physical share transfers; no requests July 2025–Jan 2026.
2
Notice Of The 34Th Annnual General Meeting Of The Company To Be Held On September 29 2026 4 Sept 2026
Intimation
Frequently Asked Questions about Emmessar Biotech & Nutrition
What does Emmessar Biotech & Nutrition Ltd do?
Emmessar Biotech & Nutrition Ltd is a standalone healthcare-products and property-leasing company. It manufactures /trades a small VedaCeuticals portfolio and earns rent from sub-leasing its MIDC Taloja industrial land; FY26 filings report Healthcare and Rent on Leasehold Land as the only operati...
Where is Emmessar Biotech & Nutrition Ltd (524768) listed?
Emmessar Biotech & Nutrition Ltd trades as EMMESSARBIOTECHLTD on the NSE and under code 524768 on the BSE.
Which sector does Emmessar Biotech & Nutrition Ltd belong to?
Emmessar Biotech & Nutrition Ltd is classified under the Chemicals sector, in the Commodity Chemicals industry.
What is the market capitalisation of Emmessar Biotech & Nutrition Ltd?
Emmessar Biotech & Nutrition Ltd has a market capitalisation of ₹12.26 Cr, which places it in the Small Cap band.
What is the PE ratio of Emmessar Biotech & Nutrition Ltd?
Emmessar Biotech & Nutrition Ltd trades at a PE ratio of 31.00, on earnings per share of ₹1.5, against a book value of ₹16.24 per share.
What is the 52-week high and low of Emmessar Biotech & Nutrition Ltd?
Over the last 52 weeks Emmessar Biotech & Nutrition Ltd has traded between ₹18.42 and ₹42.75.
What is the Return on Equity (ROE) of Emmessar Biotech & Nutrition Ltd?
Emmessar Biotech & Nutrition Ltd reported a return on equity of 4.10%. Its debt-to-equity ratio is 0.00.
Company Information
Emmessar Biotech & Nutrition Ltd is a standalone healthcare-products and property-leasing company. It manufactures /trades a small VedaCeuticals portfolio and earns rent from sub-leasing its MIDC Taloja industrial land; FY26 filings report Healthcare and Rent on Leasehold Land as the only operating segments.[1]
Website ebnl.org
Face Value ₹ 10
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/524768.md for Emmessar Biotech & Nutrition Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.